Financial Management Professionals Inc. Grows Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Financial Management Professionals Inc. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,276 shares of the biopharmaceutical company’s stock after purchasing an additional 887 shares during the period. Financial Management Professionals Inc.’s holdings in Gilead Sciences were worth $672,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Massachusetts Financial Services Co. MA raised its holdings in Gilead Sciences by 0.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock valued at $5,887,000 after buying an additional 522 shares during the last quarter. Seven Eight Capital LP purchased a new stake in shares of Gilead Sciences during the second quarter worth about $525,000. MQS Management LLC boosted its holdings in shares of Gilead Sciences by 33.9% during the second quarter. MQS Management LLC now owns 4,573 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 1,157 shares during the period. Ieq Capital LLC boosted its holdings in shares of Gilead Sciences by 3.7% during the second quarter. Ieq Capital LLC now owns 69,215 shares of the biopharmaceutical company’s stock worth $4,749,000 after purchasing an additional 2,453 shares during the period. Finally, Canada Pension Plan Investment Board boosted its holdings in shares of Gilead Sciences by 91.4% during the second quarter. Canada Pension Plan Investment Board now owns 2,699,863 shares of the biopharmaceutical company’s stock worth $185,238,000 after purchasing an additional 1,289,420 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

GILD stock opened at $91.84 on Friday. The firm has a market capitalization of $114.46 billion, a price-to-earnings ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a 50 day moving average price of $91.75 and a 200-day moving average price of $83.97. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.29 earnings per share. Equities research analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock valued at $42,130,461 over the last 90 days. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of analyst reports. Barclays increased their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. UBS Group increased their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Mizuho increased their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, Morgan Stanley upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.